Absence of *Borrelia burgdorferi* in the myocardium of subjects with normal left ventricular systolic function: a study using PCR and electron microscopy

Petr Kuchynka\textsuperscript{a,b}, Tomas Palecek\textsuperscript{a,b}, Tomas Grus\textsuperscript{c}, Jaroslav Lindner\textsuperscript{c}, Dagmar Berenovad, Zuzana Kurzovad, Pavla Balatovad, Daniel Krsek\textsuperscript{d}, Ivana Vitkovae, Eduard Nemecek\textsuperscript{e}, Jana Podzimkova\textsuperscript{a}, Anna Barbara Daneke\textsuperscript{a}, Ales Linhart\textsuperscript{e}

**Background.** Several studies have demonstrated the presence of the *Borrelia burgdorferi* (*Bb*) genome in the myocardium of patients with dilated cardiomyopathy (DCM). To further support a causal relationship between the presence of *Bb* in the heart muscle and the development of DCM, demonstration of the absence of *Bb* in the myocardium of subjects with normal left ventricular (LV) systolic function is needed.

**Aim.** To determine the prevalence of *Bb* by polymerase chain reaction (PCR) and electron microscopy (EM) in individuals with normal LV systolic function and no history suggestive of myocarditis.

**Methods.** We investigated 50 patients (67 ± 9 years, 15 women) with normal LV ejection fraction (EF) ≥ 50% undergoing cardiac surgery. During surgery, four samples from the right atrial appendage were obtained and subsequently examined by PCR and EM for the presence of *Bb*, and by immunohistochemistry to detect inflammatory cells. Serological testing of antibodies against *Bb* was also performed.

**Results.** Neither PCR nor EM detected *Bb* in any of the subjects. Immunohistological examination revealed myocardial inflammation in 2 individuals (4%). Serological analysis by enzyme-linked immunosorbent assay demonstrated IgM antibodies against *Bb* in 4% and IgG antibodies in 12% of the study cohort; Western blot revealed IgM as well as IgG positivity in 14% of patients.

**Conclusions.** The absence of *Bb* in the myocardium of individuals who undergo cardiac surgery and have normal LV systolic function supports the idea of *Bb* pathogenicity in the development of DCM.

**Key words:** *Borrelia burgdorferi*, dilated cardiomyopathy, myocarditis, myocardium

Received: May 2, 2015; Accepted with revision: September 18, 2015; Available online: October 21, 2015
http://dx.doi.org/10.5507/bp.2015.051

\textsuperscript{a2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic}

\textsuperscript{bInternational Clinical Research Center, St. Anne’s University Hospital in Brno, Czech Republic}

\textsuperscript{c2nd Department of Surgery - Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic}

\textsuperscript{dNational Institute of Public Health, Prague, Czech Republic}

\textsuperscript{eInstitute of Pathology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic}

Corresponding author: Tomas Palecek, e-mail: tpalec@lf1.cuni.cz

**INTRODUCTION**

Dilated cardiomyopathy (DCM) is a term used for dilatation and systolic dysfunction of the left ventricle (LV) (ref.\textsuperscript{1}). Dilated cardiomyopathy may develop as a consequence of acute myocarditis\textsuperscript{2}. Myocarditis and DCM are most frequently associated with viral infection of the myocardium\textsuperscript{3,4}; however, they may be also triggered by non-viral infectious agents. Within the endemic region of Central Europe there is increasing evidence that *Borrelia burgdorferi* (*Bb*) may be associated with the development of DCM (ref.\textsuperscript{5-7}).

To further support a causal relationship between the presence of *Bb* in the heart muscle and the development of DCM, demonstration of the absence of *Bb* in the myocardium of subjects with normal left ventricular (LV) systolic function is necessary. In this study we aimed to determine the prevalence of *Bb* by polymerase chain reaction (PCR) and electron microscopy (EM) in individuals with normal LV systolic function and no history suggestive of myocarditis.

**MATERIAL AND METHODS**

The study was prospectively conducted between January 2013 and September 2014. Myocardial samples from 50 adult subjects (67 ± 9 years; 15 women) with LV ejection fraction ≥ 50% undergoing myocardial revascularization and/or heart valve surgery were examined. None of the subjects had a previous history of myocarditis or a recent febrile illness, and all had normal plasma levels of CRP and white blood cells. During surgery four samples of right atrial appendage tissue were obtained. Two tissue samples were subsequently examined by PCR and EM for the presence of *Bb*, and two samples were examined...
by immunohistochemistry for inflammatory cells. Blood samples obtained from each subject were analyzed serologically for the presence of antibodies against *Bb*.

The study design was approved by the local ethics committee and informed written consent was obtained from all subjects prior to participating in this study. The investigation conforms to the principles outlined in the current Declaration of Helsinki.

**Laboratory analysis**

Four myocardial samples of right atrial appendage were taken from each study subject.

The first tissue sample was immediately placed in physiologic saline and transported to a dedicated electron microscopy laboratory where it was evaluated for the presence of *Bb*. The sample of cardiac tissue (1–2 mm³) was frozen and thawed three times. Subsequently, it was dissected in distilled water (2 mL) and stored for 20 min to lyse at room temperature. Thereafter, low speed centrifugation (665 g for 5 min) of the samples was performed to remove cell debris. The supernatants were centrifuged (11180 g for 60 min at 4°C) and sediments were re-suspended in a small amount of distilled water. Suspensions were applied onto 2400-mesh copper grids coated with 1% polyvinyl formal (Formvar) and reinforced with a carbon limit is usually 10⁶/mL if no concentration method is used and can be decreased to 5x10⁴/mL if concentration method is applied⁵.

The second myocardial sample was immediately placed in physiological saline and transported to a dedicated laboratory where it was analysed by PCR for the presence of the *Bb* genotype. A DNeasy Blood & Tissue Kit (Qiagen® GmbH, Hilden, Germany) was used for purification of total DNA from the myocardial tissue samples. Starting from ~25 mg of tissue, the protocol was followed for purification of total DNA from tissue according to the manufacturer’s instructions. DNA was eluted in a final volume of 200 μL of AE buffer. Nested PCR using ospA primers (coding for the outer surface protein A) (ref.⁶) and a real time PCR targeting 16S rRNA gene (GeneProof Borrelia burgdorferi kit, GeneProof, Czech Republic) were performed in parallel. The analytical sensitivity of the GeneProof Borrelia burgdorferi kit is 0.572 copies/μL (P = 0.05). This kit detects *Borrelia burgdorferi* sensu lato species (*B. garinii, B. afzelii, B. andersonii, B. bissettii, B. valaisiana, B. lusitaniae, B. japonica, B. tanukii, B. turdi, B. sinica*) and it doesn’t detect human DNA nor DNA of other related or unrelated pathogens. For the purpose of specificity verification and sequencing of possible positive samples, we used nested PCR targeting the OspA gene⁷. We included a positive control of genomic DNA of *Borrelia garinii* strain 192M (ref.⁸), a negative control of amplification (H₂O), and a negative control of isolation (no sample) in each run.

The remaining two samples of myocardial tissue were placed in 10% formalin solution and transported to a dedicated pathological laboratory where they were subjected to immunohistochemical analysis. Immunohistochemical analysis comprised of staining for leukocyte common antigen-positive cells (LCA+), CD3+ (T-lymphocytes) and CD68+ (macrophages) immunocompetent cells, as well as for HLA-DR positivity. Myocardial inflammation was defined as the presence of ≥14 leucocytes/mm² including ≥7 lymphocytes/mm² (ref.⁹). The enhanced expression of HLA DR (class 2 or 3) was supportive for a diagnosis of myocardial inflammation¹⁰.

Serological testing of IgM and IgG antibodies against *Bb* was based on an enzyme-linked immunosorbent assay test (ELISA, Vidia, Prague, Czech Republic) with subsequent confirmation by Western blot testing (WB, Test Line, Brno, Czech Republic).

**Statistical Analysis**

Data were expressed as means ± standard deviation or as a number and percentage of subjects, as appropriate. Statistical analysis was performed with JMP 5.1 statistical software (SAS Institute Inc., Cary, NC, USA).

**RESULTS**

The majority of study subjects (33 individuals, 66%) underwent only surgical myocardial revascularization. Isolated heart valve surgery was performed in 12 (24%) subjects and a combined surgical procedure (coronary artery bypass grafting together with heart valve surgery) was performed in 5 (10%) patients.

Using PCR and electron microscopy, no *Bb* was found in the myocardium of any of the study subjects. Immunohistochemical signs of myocardial inflammation were detected in 2 (4%) individuals (Fig 1). Enhanced HLA-DR expression was detected in just 1 of these 2 patients.

Serological analysis by ELISA demonstrated IgM antibodies against *Bb* in 2 subjects (4%) and IgG antibodies in 6 individuals (12%); WB revealed IgM as well as IgG positivity in 7 patients (14%). WB confirmed positive results gained by ELISA analysis in all subjects and found an additional 5 subjects with IgM antibodies positivity and 1 individual with IgG antibodies positivity.

**DISCUSSION**

The development of DCM is a frequently reported sequel to viral myocarditis. However, nonviral infectious agents are also involved in DCM pathogenesis. There is limited but increasing evidence that *Bb* infection can be associated with the development of DCM. *Borrelia*
*Borrelia burgdorferi* was first cultured from the myocardium of a 54-year-old man with long-standing DCM in 1990 (ref.12). On the other hand, other authors investigating myocardial samples obtained from patients with end-stage DCM using PCR were unable to detect *Bb* in any of these subjects13,14. Moreover, in endomyocardial samples (EMB) from patients with suspected inflammatory heart disease (including individuals with DCM) and *Bb* positive serology, the *Bb* genome was not revealed by PCR in any subject15.

However, in regions highly endemic for Lyme disease such as the Czech Republic, *Bb* has been repeatedly detected in the myocardium of patients with recent-onset unexplained DCM. In a pilot study from our centre, we have reported a 21% prevalence of *Bb* in EMB specimens obtained from 39 patients with recent-onset DCM (ref.15). Similar findings were subsequently published by other Czech authors6. Furthermore, in our very recently published study, the *Bb* genome was detected in 22 (20%) out of 110 patients with recent-onset unexplained DCM (ref.16). All *Bb*-positive patients were treated with intravenous ceftriaxone for 21 days in addition to conventional heart failure medication and showed significant improvement of LV ejection fraction and heart failure symptoms at one-year follow-up.

In the present study, *Bb* was not detected in the myocardial samples of any subject undergoing cardiac surgery with preserved LV systolic function, using PCR and EM. The absence of *Bb* in these individuals further supports a causal relationship between the presence of *Bb* in the heart muscle and the development of DCM.

Serological tests for antibodies to *Bb* have been the mainstay of laboratory diagnosis of Lyme disease16. However, Lyme borreliosis is primarily a clinical diagnosis and serological analysis is thus rather supportive in the diagnostic process17. In our study, ELISA detected IgM antibodies against *Bb* in 2 subjects and IgG antibodies in 6 individuals, while WB revealed IgM as well as IgG positivity in 7 patients. None of these patients had a history of Lyme disease or clinical signs suspicious of Lyme disease. It is well known that decreased specificity leading to false positivity of these serological assays could be caused by factors directly linked with the assays, such as the use of too low cut-off levels or the presence of cross-reacting antibodies18. Other factors may influence these serological methods indirectly, such as oligoclonal stimulation seen in some viral as well as non-viral infections. Moreover, in regions that are highly endemic for Lyme disease like the Czech Republic, high sero-prevalence of specific antibodies is present in the general population and the relevance to clinical disease is therefore questionable. In recent study by Kodym et al. (ref.19) sera of 100 healthy blood donors with negative history of Lyme disease were examined and serological examination revealed seropositivity in 29% of individuals. In more detail, isolated IgM antibodies against *Bb* were detected in 7% of the subjects and IgG antibodies in 17% of the healthy volunteers. Both IgM and IgG antibodies were positive in 5% of the blood donors. Based on our findings and results from other studies we think that isolated positivity of *Bb* antibodies in subjects with no clinical history and signs of Lyme disease is of limited clinical value. Finally, in our subjects with preserved LV systolic function undergoing cardiac surgery immunohistochemical signs of myocardial inflammation were extremely rare. Two subjects met the current criteria for myocardial inflammation20 but only one of these two individuals exhibited noncellular HLA-DR positivity, supporting the diagnosis of myocardial inflammation. These findings reiterate those seen in published studies and confirm the utility of the immunohistochemical criteria in the diagnosis of inflammatory DCM (ref.11,21).

**CONCLUSIONS**

The absence of *Bb*, as assessed by both PCR and EM, in the myocardium of subjects with normal LV systolic function and no history suggestive of myocarditis, supports the theory of causal relationship between *Bb* infection and DCM development.

**Acknowledgement:** The project was supported by PRVOUK-P35/LF1/5, Project reg. no. CZ.2.16/3.1.00/24012 from OP Prague Competitiveness, European Regional Development Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123) and by The Young Researchers Grant of the Czech Society of Cardiology.

**Author contribution:** PK, TP, TG, AL: study concept and design; PK, TP, TG, DB, ZK, PB, DK, IV, EN, JP, BAD: acquisition of data; PK, TP, DB, ZK, PB, DK, IV, AL: analysis and interpretation of data; PK, TP, JL, EN, JP, BAD, AL: drafting of the manuscript; PK, TP, JL, AL: critical revision of the manuscript.

**Conflicts of interest:** The authors declare there are no conflicts of interest regarding the publication of this article.
REFERENCES


